Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Frontline Selinexor(ATG-010) Plus R-CHOP Therapy for High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

NCT05422066 is registered in ClinicalTrials.gov with Li Zhiming as lead sponsor.

NCT NCT05422066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05422066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Frontline Selinexor(ATG-010) Plus R-CHOP Therapy for High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
Lead sponsor
Li Zhiming
Phase
Phase 2
Overall status
Unknown status
Start date
July 26, 2022
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl germinal center b-cell type